These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Experimental study on treating hyperlipidemic fatty liver with Taizhi'an capsule].
    Author: Sun M, Shan JZ, Zhang GP, Ying HZ.
    Journal: Zhongguo Zhong Yao Za Zhi; 2007 Apr; 32(7):616-9. PubMed ID: 17583205.
    Abstract:
    OBJECTIVE: To observe the effects of Taizhi'an capsule in treatment of hyperlipidemic fatty liver. METHOD: The model rats were induced by feeding high caloric diet for 8 weeks, then fifty rats were randomly divided into five groups, and each group had ten rats, the Taizhi'an groups (high dose 1 000 mg x kg(-1), middle dose 500 mg x kg(-1), low dose 250 mg x kg(-1)), the Yishanfu group and the model group. Liver index (liver weight/body weight), liver function, blood lipid, liver lipid, the content of MDA and SOD in liver were assayed after therapy, and observe Pathologic changes in rats liver. RESULT: Liver index, blood lipid, liver lipid, liver function increased significantly (P < 0.001) in model rats, and the content of SOD in liver decreased significantly (P < 0.05), Liver histology expressed mild to moderate fat denaturation; After being treated with high and middle dose of Taizhi'an capsule for six weeks, blood lipid, liver function decreased significantly (P < 0.001), and liver lipid decreased significantly (P < 0.001, P <0.05), the content of SOD in liver increased significantly (P < 0.05), meanwhile liver histology was closed to normal. CONCLUSION: Taizhian capsule is effective in the treatment of hyperlipidemic induced fatty liver.
    [Abstract] [Full Text] [Related] [New Search]